Long non‐coding NR2F1‐AS1 is associated with tumor recurrence in estrogen receptor‐positive breast cancers

The tenacity of late recurrence of estrogen receptor (ER)‐positive breast cancer remains a major clinical issue to overcome. The administration of endocrine therapies within the first 5 years substantially minimizes the risk of relapse; however, some tumors reappear 10–20 years after the initial dia...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Oncol
Главные авторы: Sanchez Calle, Anna, Yamamoto, Tomofumi, Kawamura, Yumi, Hironaka‐Mitsuhashi, Ai, Ono, Makiko, Tsuda, Hitoshi, Shimomura, Akihiko, Tamura, Kenji, Takeshita, Fumitaka, Ochiya, Takahiro, Yamamoto, Yusuke
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2020
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7463365/
https://ncbi.nlm.nih.gov/pubmed/32392629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12704
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы